B. Ding

发表

Pharmacokinetics and safety of co-administered paritaprevir plus ritonavir, ombitasvir, and dasabuvir in hepatic impairment.

S. Dutta, T. Marbury, E. Lawitz, 2015, Journal of hepatology.

Pharmacokinetics of Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir in Healthy Chinese Subjects and HCV GT1b-Infected Chinese, South Korean and Taiwanese Patients

R. Menon, Weihan Zhao, Katia Alves, 2018, European Journal of Drug Metabolism and Pharmacokinetics.

Effects of chronic kidney disease stage 4, end-stage renal disease, or dialysis on the plasma concentrations of ombitasvir, paritaprevir, ritonavir, and dasabuvir in patients with chronic HCV infection: pharmacokinetic analysis of the phase 3 RUBY-I and RUBY-II trials

D. Cohen, R. Menon, E. Cohen, 2018, European Journal of Clinical Pharmacology.

X. Leleu, K. Weisel, A. Zahlten-Kumeli, 2021, Leukemia & lymphoma.

Pharmacokinetics of Tacrolimus and Cyclosporine in Liver Transplant Recipients Receiving 3 Direct-Acting Antivirals as Treatment for Hepatitis C Infection

S. Dutta, E. Coakley, R. Menon, 2016, Therapeutic drug monitoring.

Drug–Drug Interactions Between the Anti-Hepatitis C Virus 3D Regimen of Ombitasvir, Paritaprevir/Ritonavir, and Dasabuvir and Eight Commonly Used Medications in Healthy Volunteers

Y. Chiu, T. Podsadecki, R. Menon, 2016, Clinical Pharmacokinetics.

Drug Interactions Between Hepatoprotective Agents Ursodeoxycholic Acid or Glycyrrhizin and Ombitasvir/Paritaprevir/Ritonavir in Healthy Japanese Subjects.

S. Dutta, R. Redman, R. Menon, 2015, Clinical therapeutics.

Pharmacokinetics and Dose Recommendations for Cyclosporine and Tacrolimus When Coadministered With ABT‐450, Ombitasvir, and Dasabuvir

S. Dutta, E. Coakley, D. Cohen, 2015, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Updated Efficacy and Safety Results of the Phase 3 Candor Study

M. Dimopoulos, D. Siegel, A. Oriol, 2020 .

Carfilzomib, dexamethasone, and daratumumab in Asian patients with relapsed or refractory multiple myeloma: post hoc subgroup analysis of the phase 3 CANDOR trial

S. Iida, Kihyun Kim, Je-Jung Lee, 2021, International Journal of Hematology.

Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study.

M. Dimopoulos, A. Jakubowiak, A. Oriol, 2021, The Lancet. Oncology.

Pharmacokinetic Evaluation of Darunavir Administered Once or Twice Daily in Combination with Ritonavir or the Three-Direct-Acting Antiviral Regimen of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Adults Coinfected with Hepatitis C and Human Immunodeficiency Viruses

R. Viani, R. Trinh, R. Menon, 2016, Antimicrobial Agents and Chemotherapy.

Pharmacokinetics of Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir in Healthy Chinese Subjects and HCV GT1b-Infected Chinese, South Korean and Taiwanese Patients

R. Menon, Weihan Zhao, N. Mobashery, 2018, European Journal of Drug Metabolism and Pharmacokinetics.

Drug-Drug Interactions between Sofosbuvir and Ombitasvir-Paritaprevir-Ritonavir with or without Dasabuvir

S. Dutta, D. Cohen, T. Podsadecki, 2015, Antimicrobial Agents and Chemotherapy.

Pharmacokinetics, Safety, and Tolerability of Glecaprevir and Pibrentasvir in Healthy White, Chinese, and Japanese Adult Subjects

S. Dutta, J. Kort, T. Podsadecki, 2017, Journal of clinical pharmacology.

Drug-Drug Interactions of Glecaprevir and Pibrentasvir Coadministered with Human Immunodeficiency Virus Antiretrovirals.

J. Kort, Stanley Wang, F. Mensa, 2020, The Journal of infectious diseases.

D. Cohen, R. Menon, E. Cohen, 2018, European Journal of Clinical Pharmacology.